The FDA in 2017 ripped Indian drugmaker Lupin in a warning letter for not learning from past mistakes. In a new visit to one of the two plants cited in that letter, the FDA has again found issues.
Each spring, tall, lush spires of brightly colored lupine blooms appear and last through the summer, feeding wildlife and endearing passersby across North America. Whether they’re annual species like ...
Months after the FDA demanded Lupin act on failures at its Mandideep, India finished dose plant, the Indian drugmaker was waiting for the other shoe to fall. It fell in a form of a warning letter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback